Immunogenicity and safety of high-dose versus double-dose quadrivalent inactivated influenza vaccine in adult kidney transplant recipients: A randomized control trial
Phase 4
Completed
- Conditions
- Kidney transplant recipientsImmunogenicity, safety, immunocompromised, solid organ transplant recipients
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Adult kidney transplant recipients (age > 15 years old) who receive immunosuppressive agents at least 3 months
Exclusion Criteria
Adult kidney transplant recipients (age > 15 years old) who receive influenza vaccination within 6 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Immunogenicity 4 weeks Heagglutination inhibition titer
- Secondary Outcome Measures
Name Time Method Adverese events 3 and 7 days Local and systemic adverese events